News

Nanochon Wins BioHealth Capital Region 6th Annual Crab Trap Competition

Nanochon, a Washington, D.C. based company in the BioHealth Capital Region, applying novel materials to replicate bone and cartilage, and high-end 3-D printing to create an implant which can permanently repair debilitating joint injuries, was selected from five finalists as the company with the most commercial potential at the 6th Annual Crab Trap Competition. This year’s judges included industry leaders Sally Allain, Head, Johnson & Johnson Innovation – JLABS @ Washington, DC, Andrea Alms, Co-Fund Manager, BioHealth Capital Fund, Lora Green, Of Counsel, Wilson Sonsini, Goodrich & Rosati, Troy LeMaile-Stovall, Chief Executive Officer, TEDCO, Conley Jones, Senior Associate, Alexandria Venture Investments, John Newby, Chief Executive Officer, Virginia Biotechnology Association, and was moderated by Rich Bendis, President & CEO, BioHealth Innovation, Inc.

The Crab Trap, presented virtually for the second year in the row due to the pandemic, was held on September 29th in association with the 7th Annual BioHealth Capital Region and 4th Annual BioHealth Capital Region Investment Conference. Nanochon CEO, Benjamin Holmes, presented on his company’s implant, which acts as both cartilage replacement and tissue growth scaffold, and is designed to be custom 3-D printed for each patient. Nanochon joins previous Crab Trap winners, BrainScope (2020), Floreo (2019), Galen Robotics (2018), LifeSprout (2017) and Sonavex (2016).

“It is a true honor to win the BioHealth Capital Region Crab Trap this year. Being an entrepreneur, especially in life sciences, is a difficult journey. Being recognized by this panel of judges is an achievement we are proud of.” said Benjamin Holmes, Nanchon CEO. “When we first created Nanochon, we were not sure we would stay in the region long term. However, the area continues to grow and provide the support and ecosystem we need to succeed and grow too.”

In addition to Nanochone, the judges and virtual audience viewed four other finalists’ presentations: Hubly SurgicalLinshomRevalo, and VNTC.

“The companies who present as part of the Crab Trap every year continue to be remarkable with their visions for the future of BioHealth.” said Richard Bendis, BHI President & CEO. “Not only do we applaud Nanochon and all the finalists this year, but also all the competitors over the past six years of this event. They truly are the future of this industry.”

Click here for a replay of the 6th Annual Crab Trap Competition is available online by

Founded in 2016, the Crab Trap Competition focuses on companies in therapeutics, diagnostics, medical devices, healthcare services, e-health, mobile health, electronic medical records, health informatics, and biohealth cyber security.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital